The Efficacy and Safety of Tenofovir Amibufenamide to Treat Low-level Viraemia After Entecavir Treatment (POWER)

Chongqing Medical University

Status

Enrolling

Conditions

Chronic Hepatitis B

Treatments

Drug: TMF

Study type

Observational

Funder types

Other

Industry

Identifiers

NCT05755776

HS-10234-A005

Details and patient eligibility

About

The goal of this observational study is to explore the efficacy and safety of Tenofovir Amibufenamide (TMF) in Entecavir (ETV) treated chronic hepatitis B patients with low-level viraemia. The main question it aims to answer is:

The efficacy and safety of TMF in chronic hepatitis B patients with low-level viraemia.
What is the appropriate treatment for ETV treated chronic hepatitis B patients with low-level viraemia.

Participants will choose to maintain their original regimen (ETV) or switch to TMF After being fully informed of the benefits and risks of treatment.

Researchers will compare ETV and TMF to see if there is a difference in the efficacy of the two drugs in chronic hepatitis B patients with low-level viraemia.

Enrollment

204 estimated patients

Sex

All

Ages

18 to 65 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Must be able to understand and sign a written informed consent, which must be obtained prior to screening.
Male and non-pregnant, non-lactating female subjects who have reached the age of 18-65 years (based on the date of signed informed consent). Female subjects of childbearing age with a negative serum pregnancy test.
Documented signs of chronic HBV infection (e.g., HBsAg positive for more than 6 months.
Subjects treated with ETV over 1 year will be able to be enrolled in the study.
Subjects with 20 ≤ HBV-DNA < 2000 IU/mL at screening (including intermittent and continuous low-level viraeima).
Must be willing and able to comply with all study requirements.

Exclusion criteria

Female patients who are pregnant or breastfeeding or who plan to become pregnant during the study period.
Men and women of childbearing potential who are unwilling to use an "effective" method of contraception as defined in the protocol during the study period.
Co-infection with HAV HCV, HIV, HDV or HEV; or co-infection with autologous liver, metabolism-related fatty liver, or drug-induced liver injury.
Diagnosis of hepatocellular carcinoma by imaging (with evidence of hepatocellular carcinoma)
Patients who have received a solid organ or bone marrow transplant
History of malignancy within 5 years prior to screening, except for specific tumors cured by surgical resection (basal cell dermal skin cancer, etc.); patients evaluated for probable malignancy were ineligible.
Currently receiving treatment with immunomodulators (e.g., corticosteroids), investigational drugs, nephrotoxic drugs, or drugs capable of regulating renal excretion. Drugs that modulate renal excretion.
Renal, cardiovascular, pulmonary, or neurological disease that is considered severe by the investigator.
Severe bone disease (e.g., osteochondrosis, chronic osteomyelitis, osteogenesis imperfecta, chondromalacia) or multiple fractures.
Subjects receiving a contraindicated combination drug (subjects receiving a contraindicated drug require a minimum 30-day washout period) and known hypersensitivity reactions to study drugs, metabolites or formulation excipients.
Current alcohol or drug abuse that, in the investigator's judgment, may interfere with the subject's compliance with study requirements.
Any other clinical condition that, in the opinion of the investigator, would render the subject unsuitable for the study or unable to comply with the dosing requirements medical condition or prior treatment.
Prior or existing clinical liver failure (Child-Pugh score ≥ grade B).